In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers ...

The company states: "Silo Pharma (SILO) announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA ...

SPC-14 has shown promising efficacy in preclinical studies, targeting both glutamate receptor NDMAR and serotonin 5-HT4 receptors, suggesting it may effectively address cognitive and ...

About SPC-15 SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA ...

ECNP 2024 Antidepressants Linked to Improved Verbal Memory Two antidepressants appeared to improve verbal memory in moderate to severe depression, an effect linked to changes in serotonin 5-HT4 ...

About SPC-15 SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA ...

SARASOTA, FL, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations ...